童仁香,陈 倩,常甄瑱,高婉卿,张 文,汪佩林.阿奇霉素序贯治疗联合硫酸特布他林对肺炎支原体肺炎患儿肺功能和血清IL-6、CRP、PCT水平的影响[J].现代生物医学进展英文版,2021,(16):3160-3163. |
阿奇霉素序贯治疗联合硫酸特布他林对肺炎支原体肺炎患儿肺功能和血清IL-6、CRP、PCT水平的影响 |
Effect of Azithromycin Sequential Therapy Combined with Terbutaline Sulfate on Pulmonary Function and Serum IL-6, CRP and PCT Levels in Children with Mycoplasma Pneumonia |
Received:February 03, 2021 Revised:February 26, 2021 |
DOI:10.13241/j.cnki.pmb.2021.16.033 |
中文关键词: 阿奇霉素 硫酸特布他林 肺功能 肺炎支原体肺炎 炎症因子 |
英文关键词: Azithromycin Terbutaline sulfate Lung function Mycoplasma pneumoniae pneumonia Inflammatory factors |
基金项目:安徽省卫计委医学科研项目(16zc044) |
|
Hits: 666 |
Download times: 357 |
中文摘要: |
摘要 目的:探讨阿奇霉素序贯治疗联合硫酸特布他林对肺炎支原体肺炎(MPP)患儿肺功能和血清白介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)水平的影响。方法:于2018年1月-2019年12月期间,选取80例来我院就诊的MPP患儿,根据入院顺序将患儿分为对照组(40例,阿奇霉素序贯治疗)和实验组(40例,阿奇霉素联合硫酸特布他林治疗),对比两组疗效、住院时间及临床症状缓解时间、肺功能、不良反应及血清炎症因子水平。结果:实验组的胸片恢复正常时间、住院时间、啰音消失时间、退热时间、咳嗽消失时间短于对照组(P<0.05)。实验组治疗后的临床总有效率95.00%(38/40)高于对照组的77.50%(31/40)(P<0.05)。实验组治疗后用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰值流速(PEF)均高于对照组,IL-6、PCT、CRP均低于对照组(P<0.05)。两组不良反应发生率组间对比无明显差异(P>0.05)。结论:阿奇霉素序贯治疗联合硫酸特布他林治疗MPP患儿,可有效缓解临床症状,降低机体炎症反应,改善患儿肺功能,不良反应轻微,协同作用显著。 |
英文摘要: |
ABSTRACT Objective: To investigate the effect of Azithromycin Sequential Therapy Combined with terbutaline sulfate on pulmonary function and serum levels of interleukin-6 (IL-6), procalcitonin (PCT) and C-reactive protein (CRP) in children with Mycoplasma pneumoniae pneumonia (MPP). Methods: 80 children with MPP were selected from January 2018 to December 2019, and they were divided into control group (40 cases, azithromycin sequential treatment) and experimental group (40 cases, Azithromycin combined with terbutaline sulfate treatment) according to the order of admission. The curative effect, clinical symptom remission time, lung function, adverse reactions and serum inflammatory factors were compared between the two groups. Results: The recovery time of chest X-ray, hospitalization time, rales disappearance time, fever abatement time and cough disappearance time of the experimental group were shorter than those of the control group (P<0.05). The clinical total effective rate of the experimental group after treatment was 95.00% (38/40), which was higher than 77.50% (31/40) of the control group (P<0.05). After treatment, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF) of the experimental group were higher than those of the control group, while IL-6, PCT and CRP of the experimental group were lower than those of the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Azithromycin Sequential Therapy Combined with terbutaline sulfate in the treatment of MPP children can effectively relieve the clinical symptoms, reduce the inflammatory reaction and improve the lung function of children, with mild adverse reactions and significant synergistic effect. |
View Full Text
View/Add Comment Download reader |
Close |